014950 — Samik Pharm Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Samik Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts
Standards:	KAS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	46,759	51,229	55,857	60,020
Cost of Revenue
Gross Profit	—	33,935	38,805	42,360
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	—	48,433	52,203	56,748
Operating Profit	—	2,796	3,654	3,273
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	367	3,423	4,353	48.5
Provision for Income Taxes
Net Income After Taxes	—	2,969	3,522	-755
Net Income Before Extraordinary Items
Net Income	—	2,969	3,522	-755
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	—	2,969	3,522	-755
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	—	324	385	-103
Dividends per Share